U028 A Practical Approach to the Management of Onychomycosis
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session is a fast-paced comprehensive review of diagnosis and management of onychomycosis in 2024. Topics covered include epidemiology, diagnosis, and treatment in both adults and children. FDA approved oral and topical treatments will be discussed in detail, as well as, emerging therapies such as devices. Dermatophytoma and emergence of antifungal resistance will be reviewed. We will also discuss adverse events of treatments will be discussed. Faculty include nail experts from around the world.
LEARNING OBJECTIVES
Utilize clinicopathologic correlation for improved diagnosis and treatment of onychomycosis.
Summarize current and emerging treatments for onychomycosis.
Assess for antifungal resistance when treating onychomycosis.
SCHEDULE
3:30 PM
Epidemiology of Onychomycosis
Aditya K. Gupta, MD, PhD, FAAD
3:35 PM
Traditional Diagnosis and PCR
Molly A. Hinshaw, MD, FAAD
3:45 PM
Antifungal Resistance, Dermatophytomas, Topicals
Shari Lipner, MD, PhD, FAAD
3:55 PM
Orals, Prevention of Recurrence
Aditya K. Gupta, MD, PhD, FAAD
4:05 PM
Antifungal Safety
Shari Lipner, MD, PhD, FAAD
4:10 PM
Devices, Conclusions
Shari Lipner, MD, PhD, FAAD
4:15 PM
Questions and Answers
SPEAKERS
Aditya K. Gupta, MD, PhD, FAAD
Molly A. Hinshaw, MD, FAAD
Shari Lipner, MD, PhD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Aditya K. Gupta, MD, PhD, FAAD
Bausch Health – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Emblation Limited – Investigator(Grants/Research Funding); Moberg Derma – Consultant(Fees); Ortho Dermatologics – Consultant(Fees);
Molly A. Hinshaw, MD, FAAD
Accure Medical, Inc – Founder(Stock);
Shari Lipner, MD, PhD, FAAD
BelleTorus Corporation – Investigator(Grants/Research Funding); Moberg Pharma North America LLC – Investigator(Grants/Research Funding);